Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
101-120 of 998 trials

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Herpes Zoster Vaccine for Immunocompromised Kids

We are studying a new vaccine for children aged 1 to 17 who have had kidney transplants. The trial will help us understand its safety and how well it triggers an immune response.

Prevention of Shingles in Immunocompromised Children1-2 yearsEfficacy phase (II)No PlaceboCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePediatrics

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Melanoma Treatment: Fianlimab and Cemiplimab Study

We are investigating whether combining fianlimab and cemiplimab is safer and more effective than cemiplimab alone for adults with resectable stage III or IV melanoma. This study aims to see how well these treatments work before surgery.

Malignant Melanoma>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Idiopathic Pulmonary Fibrosis: Axatilimab Study

We are testing a new medication, axatilimab, for people with idiopathic pulmonary fibrosis to see if it improves lung function and overall quality of life compared to a placebo.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Severe Infections: MODIFY Trial

We are testing a new method to guide antibiotic treatment for severe infections, aiming to reduce unnecessary antibiotic use. This study will also evaluate how this approach impacts recovery and health outcomes.

Sepsis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Clostridioides difficile Infection: VE303 Treatment Study

We are testing a new treatment, VE303, to see if it helps prevent recurrent Clostridioides difficile infections in people who have had this infection before. The study will also evaluate safety and quality of life for participants.

Clostridioides difficile Infection6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInfectious Diseases

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Rheumatoid Arthritis: LY3871801 Study

We are testing a new medication, LY3871801, for adults with moderately-to-severely active rheumatoid arthritis. The study aims to see if it can reduce disease activity better than a placebo.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Vericiguat for Vasospastic Angina

We are studying how vericiguat affects heart function and angina episodes in patients with vasospastic angina. The trial also looks at quality of life and safety of the treatment.

Vasospastic Angina1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteCardiologyInternal Medicine

TAK-330 for Reversing Blood Thinner Effects in Urgent Surgery

We are studying whether TAK-330 can effectively reverse the effects of certain blood thinners in patients needing urgent surgery. This trial compares TAK-330 to the standard treatment to see which works better.

Patients on Factor Xa Inhibitors Needing Urgent Intervention≤3 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Castration-Resistant Prostate Cancer: Lutetium [177Lu] VIPIVOTIDE TETRAXETAN

We are studying a new treatment for men with castration-resistant prostate cancer to see how well it works alone and with other medications. The goal is to evaluate its effects on prostate-specific antigen (PSA) levels and overall health.

Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteOncology

Head and Neck Cancer: VB10.16 and Pembrolizumab

We are studying the safety and effectiveness of a new treatment combining VB10.16 with pembrolizumab for patients with HPV16-positive head and neck cancer. This trial aims to find the best dose and evaluate how well this combination works against the cancer.

Head and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Follicular Lymphoma: Odronextamab vs. Rituximab

We are studying whether odronextamab combined with lenalidomide is safer and more effective than rituximab combined with lenalidomide for adults with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Marginal Zone LymphomaFollicular Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Kidney Cancer: Savolitinib Plus Durvalumab Study

We are exploring whether a new combination treatment can help patients with advanced papillary renal cell carcinoma live longer and feel better compared to standard therapies.

Clear Cell Papillary Renal Cell CarcinomaConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology